1Clemmesen JO, Galatius S, Skak C, et al. The effect of increasing blood pressure with dopamine on systemic, splanchnic, and lower extremity hemodynamics in patients with acute liver failure[J]. Scand J Gastroenterol, 1999, 34(9):921-927.
2Olson D, Pohlman A, Hall JB. Administration of low-dose dopamine to nonoliguric patients with sepsis syndrome does not raise intramucosal gastric pH nor improve creatinine clearance[J]. Am J Respir Crit Care Med, 1996, 154(6 Pt 1):1664-1670.
3Bellomo R, Chapman M, Finfer S,et al. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled andomized trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group[J]. Lancet, 2000, 356(9248):2139-2143.
4Juste RN, Panikkar K, Soni N. The effects of low-dose dopamine infusions on haemodynamic and renal parameters in patients with septic shock requiring treatment with noradrenaline[J]. Intensive Care Med, 1998, 24(6):564-568.
5D'Orio V, el Allaf D, Juchmes J,et al. The use of low doses of dopamine in intensive care medicine[J]. Arch Int Physiol Biochim, 1984, 92(4):S11-S20.
6Chamorro C, Romera MA, Martinez-Melgar JL, et al. Dopamine dose and renal damage[J]. Lancet, 2001, 357(9269):1707-1708.
7Dellinger RP, Carlet JM, Masur H, et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock[J]. Crit Care Med, 2004, 32(3):858-873.
8Devins SS, Miller A, Herndon BL,et al. Effects of dopamine on T-lymphocyte proliferative responses and serum prolactin concentrations in critically ill patients[J]. Crit Care Med, 1992, 20(12):1644-1649.
9Van den Berghe G, de Zegher F, Lauwers P,et al. Growth hormone secretion in critical illness: effect of dopamine[J]. J Clin Endocrinol Metab, 1994, 79(4):1141-1146.
10Van den Berghe G, de Zegher F, Lauwers P. Dopamine suppresses pituitary function in infants and children[J]. Crit Care Med, 1994, 22(11):1747-1753.
二级参考文献13
1[1]Australian and New Zealand Intensive Care Society. Low-dose dopamine in patients with early renal dysfunction:a placebo-controlled randomised trial. ANZICS Clinical Trials Group. Lancet, 2000,356 (9248): 2139 - 2143
2[2]Ruokonen E, Parviainen I, Uusaro A. Treatment of impaired perfusion in septic shock. Ann Med ,2002,34:590- 597
3[3]Tsuneyoshi I,Yamada H, Kakihana Y. Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med ,2001 ,29(3) :487 - 93
4[4]Patel BM, Chittock DR, Russell JA, et al. Beneficial effects of shot-term vasopressin infusion during severe septic shock. Anesthesiology, 2002,96(3) :576 - 582
5[5]Kahn JM, Kress JP, Hall JB. Skin necrosis after extravasation of low-dose vasopressin administered for septic shock. Crit Care Med, 2002,30( 8 ):1899- 1901
6[6]Leone M, Bourgoin A, Cambon S,et al. Empirical antimicrobial therapy of septic shock patients: adequacy and impact on the outcome. Crit Care Med,2003 ,31(2) :462 - 467
7[7]Manthous CA, Hall JB, Kushner R, et al. The effect of mechanical ventila tion on oxygen consumption in critically ill patients. Am J Respir Crit Care Med ,1995,151(1) :210- 214
8[8]Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA, 2002, , 288 (7): 862 - 871
9[9]Keh D, Boehnke T, Weber-Cartens S, et al. Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med,2003,167(4) :512 - 520
10[10]Kirov MY,Evgenov OV,Evgenov NV,et al. Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. Crit Care Med, 2001 ,29(10): 1860 - 1867
